ULTIVA® (remifentanil HCl) Plans 1.5
Continue to app
Free Version
Publisher Description
Put Remi anesthesia plans at your fingertips. This app gives you easy access to plans featuring ULTIVA (remifentanil HCl) for Injection as an analgesic. Learn from plans for craniotomy, spine, fast-track cardiac, and more. Expand your knowledge with a variety of TIVA and balanced anesthesia plans. Verify Remi dosing with a guide that is both easy to access and use. THIS APP IS INTENDED ONLY FOR ANESTHESIA PROVIDERS IN THE UNITED STATES. USE OF ANY DRUG, THERAPEUTIC REGIMEN, OR MEDICAL TECHNIQUE MENTIONED IN THIS APP IS SUBJECT TO THE INDEPENDENT KNOWLEDGE AND JUDGMENT OF THE PRACTITIONER. INDICATIONS AND IMPORTANT RISK INFORMATION INDICATIONS ULTIVA (remifentanil HCl) for Injection is indicated for intravenous administration: As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting As an analgesic component of monitored anesthesia care in adult patients IMPORTANT RISK INFORMATION Due to the presence of glycine in the formulation, ULTIVA is contraindicated for epidural or intrathecal administration. ULTIVA is also contraindicated in patients with known hypersensitivity to fentanyl analogs. Vital signs and oxygenation must be continuously monitored during ULTIVA administration. ULTIVA produces adverse events that are characteristic of -opioids, such as respiratory depression, apnea, tachycardia, bradycardia, hypotension, hypertension, and skeletal muscle (including chest wall) rigidity. Because these effects are dosedependent and can occur rapidly, continuous monitoring is necessary. ULTIVA should not be used as a sole agent because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity, and tachycardia. Continuous infusions of ULTIVA should be administered only by an infusion device. IV bolus administration of ULTIVA should be used only during the maintenance of general anesthesia. In nonintubated patients, single doses of ULTIVA should be administered over 30 to 60 seconds. Interruption of an infusion of ULTIVA will result in rapid offset of effect. Rapid clearance and lack of drug accumulation result in rapid dissipation of respiratory depressant and analgesic effects (within 5 to 10 min) upon discontinuation of ULTIVA at recommended doses. Discontinuation of an infusion of ULTIVA should be preceded by the establishment of adequate postoperative analgesia particularly where postoperative pain is anticipated. ULTIVA should be used with caution in pediatric, geriatric, and morbidly obese patients due to high variability in pharmacodynamics and dose/response. Intraoperative awareness has been reported with concomitant administration with propofol infusion 75 mcg/kg/min. Failure to adequately clear the IV tubing to remove residual ULTIVA has been associated with the appearance of respiratory depression, apnea, and muscle rigidity upon the administration of additional fluids or medications through the same IV tubing. ULTIVA SHOULD BE USED IN CAREFULLY MONITORED SETTINGS BY SPECIFICALLY TRAINED PERSONS NOT INVOLVED IN THE SURGICAL OR DIAGNOSTIC PROCEDURE. OXYGEN SATURATION IS TO BE CONTINUOUSLY MONITORED. RESUSCITATIVE AND INTUBATION EQUIPMENT, OXYGEN, AND AN OPIOID ANTAGONIST MUST BE READILY AVAILABLE. Please visit www.ultiva.com to download the ULTIVA full Prescribing Information for all indications, precautions, warnings, contraindications, and adverse events. If you have questions or comments, please call us at 800.RX.MYLAN. ULTIVA is a registered trademark of Glaxo Group Limited. The Mylan logo is a registered trademark of Mylan Inc.
Requires iOS 8.1 or later. Compatible with iPhone, iPad, and iPod touch.
About ULTIVA® (remifentanil HCl) Plans
ULTIVA® (remifentanil HCl) Plans is a free app for iOS published in the Health & Nutrition list of apps, part of Home & Hobby.
The company that develops ULTIVA® (remifentanil HCl) Plans is Mylan Inc.. The latest version released by its developer is 1.5.
To install ULTIVA® (remifentanil HCl) Plans on your iOS device, just click the green Continue To App button above to start the installation process. The app is listed on our website since 2015-06-26 and was downloaded 4 times. We have already checked if the download link is safe, however for your own protection we recommend that you scan the downloaded app with your antivirus. Your antivirus may detect the ULTIVA® (remifentanil HCl) Plans as malware if the download link is broken.
How to install ULTIVA® (remifentanil HCl) Plans on your iOS device:
- Click on the Continue To App button on our website. This will redirect you to the App Store.
- Once the ULTIVA® (remifentanil HCl) Plans is shown in the iTunes listing of your iOS device, you can start its download and installation. Tap on the GET button to the right of the app to start downloading it.
- If you are not logged-in the iOS appstore app, you'll be prompted for your your Apple ID and/or password.
- After ULTIVA® (remifentanil HCl) Plans is downloaded, you'll see an INSTALL button to the right. Tap on it to start the actual installation of the iOS app.
- Once installation is finished you can tap on the OPEN button to start it. Its icon will also be added to your device home screen.
